Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

afamitresgene autoleucel

View Patient Information
A preparation of autologous human T lymphocytes transduced with a lentiviral vector encoding an affinity-enhanced T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A2-restricted peptide human melanoma antigen A4 (MAGE-A4) C1032, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, afamitresgene autoleucel targets and binds to tumor cells expressing MAGE-A4. This results in cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen (TAA) MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:afami-cel
autologous genetically-modified MAGE-A4 C1032 T cells
autologous genetically-modified MAGE-A4 C1032 T lymphocytes
MAGE-A4 SPEAR T cells
MAGE-A4C1032T
SPEAR T-cell ADP-A2M4
US brand name:Tecelra
Code name:ADP-A2M4
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search